Polaris Bio closes RMB70m Series B round led by Delian Capital

Polaris Bio recently announced that it has completed 70 million yuan in a Series B financing round. This round was led by Delian Capital, with participation from Volcanics Venture, Baidu Ventures, ETP, Wuxi Financial, Ascendin Fund, and Morningside Venture Capital.

Polaris Bio recently announced that it has completed 70 million yuan in a Series B financing round. This round was led by Delian Capital, with participation from Volcanics Venture, Baidu Ventures, ETP, Wuxi Financial, Ascendin Fund, and Morningside Venture Capital.

Founded in 2016, Polaris Bio is a medical technology company focused on the development and clinical application of single-cell precision diagnostic technology.

Polaris Bio is committed to revealing individual differences and dynamic changes in patients through single-cell technology to support clinical accompanying diagnosis and precision treatment.

Proceeds from this round of financing will be mainly used to advance the layout of the single-cell diagnostic platform with mass spectrometry flow-through technology as its core, accelerate the registration filing and commercialization of the system as a clinical diagnostic product, and further develop R&D collaboration with clinical experts and innovative pharmaceutical companies.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/06/25/polaris-bio-closes-rmb70m-series-b-round-led-by-delian-capital/.

Leave a Reply

Please Login to Comment